STOCK TITAN

Keros CSO sells 3,568 shares in tax sell-to-cover

(Neutral)
(Negative)
Form Type
4

Rhea-AI Filing Summary

Keros Therapeutics, Inc. (KROS) reported that Chief Scientific Officer Lorena Raquel Lerner sold 3,568 shares of common stock on 2026-08-18 at a weighted average price of $10.29 per share, in automatic "sell-to-cover" transactions for tax withholding on vesting RSUs. Following these sales, she held 27,559 shares of common stock directly.

Positive

  • None.

Negative

  • None.
Insider Lerner Lorena Raquel
Role Chief Scientific Officer
Sold 3,568 shs ($37K)
Type Security Shares Price Value
Sale Common Stock F1, F2 3,568 $10.29 $37K
Holdings After Transaction: Common Stock — 27,559 shares (Direct)
Footnotes (2)
  1. F1. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
  2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.14 to $10.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Shares sold 3,568 shares of Common Stock Sale on 2026-08-18 by Chief Scientific Officer Lorena Raquel Lerner
Weighted average sale price $10.29 per share Weighted average price for 3,568 Keros Therapeutics shares sold
Sale price range $10.14 to $10.50 per share Multiple transactions within this price range on 2026-08-18
Shares owned after transaction 27,559 shares of Common Stock Direct ownership by Lorena Raquel Lerner following the sale
sell-to-cover financial
"The Issuer has adopted a "sell-to-cover" policy to satisfy the tax"
Sell-to-cover is when part of newly issued or exercised company stock is immediately sold to pay required taxes and fees, so the recipient keeps the remaining shares. For investors this matters because it reduces the number of shares insiders or employees actually hold after a grant, can create small, routine share sales that aren’t signal of cashing out, and slightly increases share supply on the market—like selling a portion of a paycheck to cover the tax bill.
restricted stock units financial
"obligations in connection with the vesting of restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
tax withholding obligations financial
"shares required to be sold by the Reporting Person to cover tax withholding"

FAQ

What insider transaction did KROS disclose for Lorena Raquel Lerner?

Keros Therapeutics disclosed that Chief Scientific Officer Lorena Raquel Lerner sold 3,568 shares of common stock on 2026-08-18 in automatic sell-to-cover transactions to satisfy tax withholding obligations related to vesting restricted stock units.

At what price were the KROS shares sold in this Form 4 filing?

The reported sale price for Keros Therapeutics (KROS) shares was a weighted average of $10.29 per share. The 3,568 shares were sold in multiple transactions at prices ranging from $10.14 to $10.50 per share, inclusive.

How many KROS shares does Lorena Raquel Lerner own after the reported sale?

After the reported transactions, Chief Scientific Officer Lorena Raquel Lerner directly held 27,559 shares of Keros Therapeutics common stock. This figure reflects her ownership immediately following the 3,568-share sell-to-cover sale on 2026-08-18.

Why did the KROS insider sell 3,568 shares in this Form 4?

The 3,568 shares were sold under Keros Therapeutics’ “sell-to-cover” policy. The filing states the sales represented shares required to cover tax withholding obligations from the vesting of restricted stock units and were automatic, not at her discretion.

Was the KROS insider sale made under a Rule 10b5-1 trading plan?

The filing does not state that the transactions were made under a Rule 10b5-1 trading plan. Instead, it explains that the sales were automatic sell-to-cover transactions pursuant to the issuer’s policy for tax withholding on vesting restricted stock units.

What type of security was involved in the KROS Form 4 transaction?

The transaction reported for Keros Therapeutics (KROS) involved Common Stock. The 3,568 shares sold were common shares, disposed of to satisfy tax withholding obligations arising from the vesting of restricted stock units held by the reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lerner Lorena Raquel

(Last)(First)(Middle)
C/O KEROS THERAPEUTICS, INC.
1050 WALTHAM STREET, SUITE 302

(Street)
LEXINGTON MASSACHUSETTS 02421

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Keros Therapeutics, Inc. [ KROS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Scientific Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/18/2026S3,568(1)D$10.29(2)27,559D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.14 to $10.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Esther Cho, Attorney-in-Fact08/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)